Kevin Deane
Concepts (403)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Arthritis, Rheumatoid | 109 | 2024 | 990 | 18.490 |
Why?
| Autoantibodies | 62 | 2024 | 1335 | 7.580 |
Why?
| Rheumatoid Factor | 36 | 2023 | 156 | 5.850 |
Why?
| Anti-Citrullinated Protein Antibodies | 22 | 2023 | 89 | 4.680 |
Why?
| Peptides, Cyclic | 29 | 2023 | 260 | 3.590 |
Why?
| Autoimmunity | 22 | 2023 | 831 | 3.580 |
Why?
| Antirheumatic Agents | 11 | 2021 | 254 | 2.080 |
Why?
| Rheumatic Diseases | 4 | 2022 | 49 | 1.980 |
Why?
| Sputum | 4 | 2021 | 291 | 1.660 |
Why?
| Immunoglobulin A | 11 | 2023 | 174 | 1.310 |
Why?
| Lung Diseases, Interstitial | 8 | 2024 | 464 | 1.300 |
Why?
| Biomarkers | 27 | 2024 | 3590 | 1.130 |
Why?
| Autoantigens | 8 | 2023 | 397 | 1.110 |
Why?
| Humans | 132 | 2024 | 119032 | 1.090 |
Why?
| Bronchial Diseases | 3 | 2013 | 34 | 0.970 |
Why?
| Disease Progression | 16 | 2021 | 2490 | 0.960 |
Why?
| Early Medical Intervention | 2 | 2014 | 56 | 0.960 |
Why?
| Extracellular Traps | 3 | 2021 | 40 | 0.950 |
Why?
| Genetic Predisposition to Disease | 16 | 2023 | 2275 | 0.910 |
Why?
| Rheumatology | 6 | 2021 | 87 | 0.860 |
Why?
| Lung Diseases | 4 | 2022 | 718 | 0.850 |
Why?
| Early Diagnosis | 8 | 2022 | 230 | 0.840 |
Why?
| Mosquito Vectors | 1 | 2022 | 21 | 0.840 |
Why?
| Insecticides | 1 | 2022 | 31 | 0.820 |
Why?
| Lupus Erythematosus, Systemic | 4 | 2022 | 227 | 0.820 |
Why?
| Inflammation | 9 | 2023 | 2571 | 0.810 |
Why?
| Joints | 4 | 2015 | 85 | 0.810 |
Why?
| Precision Medicine | 3 | 2020 | 363 | 0.800 |
Why?
| Malaria | 1 | 2022 | 60 | 0.790 |
Why?
| Arthralgia | 2 | 2021 | 51 | 0.790 |
Why?
| Prodromal Symptoms | 1 | 2020 | 13 | 0.780 |
Why?
| Middle Aged | 62 | 2022 | 27627 | 0.760 |
Why?
| Risk Factors | 29 | 2022 | 9003 | 0.760 |
Why?
| Epitopes | 8 | 2023 | 443 | 0.750 |
Why?
| Histones | 4 | 2023 | 552 | 0.700 |
Why?
| Citrullination | 2 | 2020 | 12 | 0.690 |
Why?
| Lung | 7 | 2020 | 3666 | 0.690 |
Why?
| Female | 78 | 2023 | 61588 | 0.690 |
Why?
| Enzyme-Linked Immunosorbent Assay | 6 | 2023 | 827 | 0.670 |
Why?
| Male | 67 | 2022 | 57818 | 0.670 |
Why?
| HIV Infections | 3 | 2021 | 2461 | 0.640 |
Why?
| Methotrexate | 3 | 2021 | 227 | 0.630 |
Why?
| Mucous Membrane | 1 | 2018 | 113 | 0.630 |
Why?
| Asymptomatic Diseases | 2 | 2021 | 81 | 0.610 |
Why?
| Immunoglobulin G | 11 | 2023 | 788 | 0.610 |
Why?
| Pedigree | 2 | 2020 | 485 | 0.590 |
Why?
| Citrulline | 2 | 2016 | 41 | 0.580 |
Why?
| Adult | 48 | 2022 | 31525 | 0.580 |
Why?
| Synovitis | 2 | 2023 | 24 | 0.580 |
Why?
| Antibodies, Anti-Idiotypic | 2 | 2015 | 56 | 0.560 |
Why?
| Transients and Migrants | 1 | 2016 | 22 | 0.560 |
Why?
| Human Migration | 1 | 2016 | 21 | 0.560 |
Why?
| Case-Control Studies | 15 | 2023 | 3173 | 0.550 |
Why?
| Autoimmune Diseases | 4 | 2023 | 398 | 0.540 |
Why?
| Arthritis | 2 | 2016 | 112 | 0.540 |
Why?
| Immunoglobulin M | 7 | 2023 | 253 | 0.520 |
Why?
| Aged | 34 | 2022 | 19661 | 0.520 |
Why?
| Family | 7 | 2021 | 587 | 0.500 |
Why?
| Cytokines | 10 | 2023 | 1900 | 0.490 |
Why?
| Sexual Behavior | 2 | 2016 | 437 | 0.490 |
Why?
| Pneumonia | 1 | 2020 | 592 | 0.490 |
Why?
| Prospective Studies | 19 | 2022 | 6477 | 0.480 |
Why?
| Risk-Taking | 1 | 2016 | 319 | 0.460 |
Why?
| Endothelium, Vascular | 4 | 2013 | 907 | 0.450 |
Why?
| Chemokines | 2 | 2012 | 230 | 0.450 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2013 | 45 | 0.440 |
Why?
| Tanzania | 3 | 2021 | 45 | 0.440 |
Why?
| Risk Reduction Behavior | 1 | 2014 | 199 | 0.440 |
Why?
| Hazardous Substances | 1 | 2012 | 12 | 0.430 |
Why?
| Observational Studies as Topic | 2 | 2024 | 89 | 0.430 |
Why?
| Mass Screening | 3 | 2020 | 1052 | 0.410 |
Why?
| Susac Syndrome | 1 | 2011 | 3 | 0.400 |
Why?
| Fatty Acids, Omega-3 | 3 | 2017 | 125 | 0.390 |
Why?
| Smoking | 9 | 2024 | 1487 | 0.380 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 70 | 0.380 |
Why?
| Protein Processing, Post-Translational | 1 | 2013 | 408 | 0.380 |
Why?
| Gene-Environment Interaction | 1 | 2012 | 201 | 0.380 |
Why?
| Emigration and Immigration | 1 | 2010 | 47 | 0.370 |
Why?
| Malondialdehyde | 2 | 2020 | 30 | 0.370 |
Why?
| Acetaldehyde | 2 | 2020 | 20 | 0.370 |
Why?
| Research Design | 3 | 2024 | 969 | 0.370 |
Why?
| Health Fairs | 1 | 2009 | 9 | 0.360 |
Why?
| Antibodies, Antinuclear | 5 | 2023 | 55 | 0.360 |
Why?
| Postmenopause | 7 | 2023 | 306 | 0.360 |
Why?
| Glucocorticoids | 3 | 2021 | 547 | 0.330 |
Why?
| Antibodies, Bacterial | 3 | 2023 | 126 | 0.330 |
Why?
| Mucin-5B | 2 | 2022 | 175 | 0.330 |
Why?
| Incidence | 9 | 2021 | 2424 | 0.320 |
Why?
| Synovial Membrane | 3 | 2023 | 72 | 0.320 |
Why?
| Health Behavior | 3 | 2018 | 720 | 0.300 |
Why?
| Cross-Sectional Studies | 9 | 2023 | 4552 | 0.290 |
Why?
| Antibody Formation | 4 | 2023 | 276 | 0.280 |
Why?
| Antibodies, Antiphospholipid | 1 | 2005 | 22 | 0.270 |
Why?
| Vasculitis | 1 | 2005 | 75 | 0.260 |
Why?
| Risk Assessment | 6 | 2020 | 3057 | 0.240 |
Why?
| Qualitative Research | 2 | 2021 | 953 | 0.240 |
Why?
| Polysaccharides | 2 | 2017 | 78 | 0.240 |
Why?
| Risk | 3 | 2016 | 854 | 0.230 |
Why?
| Estrogens | 3 | 2017 | 329 | 0.230 |
Why?
| Protein-Arginine Deiminases | 3 | 2021 | 17 | 0.220 |
Why?
| Time Factors | 6 | 2019 | 6414 | 0.220 |
Why?
| Mouth Mucosa | 3 | 2023 | 82 | 0.220 |
Why?
| Periodontal Diseases | 1 | 2023 | 58 | 0.220 |
Why?
| Immunoglobulin Isotypes | 1 | 2022 | 32 | 0.220 |
Why?
| Trichloroethylene | 1 | 2022 | 7 | 0.220 |
Why?
| Insecticide-Treated Bednets | 1 | 2022 | 3 | 0.210 |
Why?
| Biological Products | 2 | 2022 | 170 | 0.210 |
Why?
| Prevalence | 4 | 2022 | 2326 | 0.210 |
Why?
| Women's Health | 5 | 2017 | 274 | 0.210 |
Why?
| Patient Education as Topic | 2 | 2018 | 699 | 0.200 |
Why?
| Sex Factors | 5 | 2020 | 1781 | 0.200 |
Why?
| Hemorrhage | 1 | 2005 | 623 | 0.200 |
Why?
| Organ Specificity | 2 | 2019 | 278 | 0.200 |
Why?
| Epstein-Barr Virus Infections | 1 | 2022 | 73 | 0.190 |
Why?
| Sarcoidosis | 1 | 2022 | 130 | 0.190 |
Why?
| Housing | 1 | 2022 | 123 | 0.190 |
Why?
| Fatty Acids, Unsaturated | 1 | 2021 | 86 | 0.190 |
Why?
| Neutrophil Activation | 1 | 2021 | 100 | 0.190 |
Why?
| Retrospective Studies | 5 | 2024 | 12990 | 0.190 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 15 | 1 | 2020 | 8 | 0.190 |
Why?
| Hydroxychloroquine | 1 | 2020 | 59 | 0.190 |
Why?
| Chemokine CXCL16 | 1 | 2020 | 4 | 0.190 |
Why?
| Social Stigma | 1 | 2021 | 87 | 0.190 |
Why?
| Museums | 1 | 2000 | 8 | 0.180 |
Why?
| Severity of Illness Index | 8 | 2022 | 2674 | 0.180 |
Why?
| Complement System Proteins | 2 | 2022 | 294 | 0.180 |
Why?
| Toll-Like Receptors | 1 | 2020 | 167 | 0.180 |
Why?
| Sjogren's Syndrome | 1 | 2020 | 40 | 0.180 |
Why?
| Intestines | 2 | 2021 | 332 | 0.180 |
Why?
| Bacteriophages | 1 | 2021 | 76 | 0.180 |
Why?
| Muramidase | 1 | 2020 | 72 | 0.180 |
Why?
| Public-Private Sector Partnerships | 1 | 2020 | 43 | 0.180 |
Why?
| Art Therapy | 1 | 2000 | 16 | 0.180 |
Why?
| Cytomegalovirus Infections | 1 | 2022 | 187 | 0.180 |
Why?
| Lipopolysaccharide Receptors | 1 | 2020 | 88 | 0.180 |
Why?
| Animals | 8 | 2022 | 33399 | 0.180 |
Why?
| Attitude | 1 | 2021 | 231 | 0.180 |
Why?
| Age Factors | 7 | 2020 | 2995 | 0.170 |
Why?
| Nuclear Family | 1 | 2019 | 54 | 0.170 |
Why?
| Occupational Exposure | 1 | 2022 | 277 | 0.170 |
Why?
| Young Adult | 8 | 2021 | 10799 | 0.170 |
Why?
| Inflammation Mediators | 2 | 2020 | 502 | 0.170 |
Why?
| Gain of Function Mutation | 1 | 2018 | 30 | 0.170 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2016 | 46 | 0.170 |
Why?
| Dexamethasone | 1 | 2020 | 320 | 0.170 |
Why?
| Arthritis, Experimental | 1 | 2020 | 133 | 0.160 |
Why?
| Gene Expression | 2 | 2022 | 1492 | 0.160 |
Why?
| Cellular Senescence | 1 | 2019 | 151 | 0.160 |
Why?
| Cohort Studies | 10 | 2022 | 5117 | 0.160 |
Why?
| Monocytes | 1 | 2020 | 513 | 0.160 |
Why?
| HLA-DR4 Antigen | 3 | 2007 | 75 | 0.150 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 509 | 0.150 |
Why?
| Vascular Stiffness | 2 | 2013 | 425 | 0.150 |
Why?
| Metabolome | 1 | 2020 | 296 | 0.150 |
Why?
| Global Health | 1 | 2020 | 310 | 0.150 |
Why?
| Remission Induction | 2 | 2021 | 247 | 0.150 |
Why?
| Galactose | 1 | 2017 | 20 | 0.150 |
Why?
| United States | 8 | 2022 | 12557 | 0.150 |
Why?
| Idiopathic Pulmonary Fibrosis | 2 | 2019 | 451 | 0.150 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2021 | 1175 | 0.150 |
Why?
| Glycosylation | 1 | 2017 | 129 | 0.150 |
Why?
| Military Personnel | 2 | 2021 | 529 | 0.150 |
Why?
| Clinical Trials as Topic | 1 | 2021 | 968 | 0.140 |
Why?
| Seroepidemiologic Studies | 3 | 2014 | 146 | 0.140 |
Why?
| Coronary Disease | 2 | 2017 | 356 | 0.140 |
Why?
| Adiponectin | 1 | 2018 | 226 | 0.140 |
Why?
| Sex Work | 1 | 2016 | 17 | 0.140 |
Why?
| Estradiol | 3 | 2017 | 476 | 0.140 |
Why?
| Plasma Cells | 1 | 2016 | 59 | 0.140 |
Why?
| Hydrolases | 2 | 2021 | 51 | 0.140 |
Why?
| HLA Antigens | 1 | 2017 | 230 | 0.140 |
Why?
| Sensitivity and Specificity | 3 | 2018 | 1795 | 0.140 |
Why?
| Diagnosis, Differential | 3 | 2013 | 1384 | 0.130 |
Why?
| Peptides | 1 | 2021 | 879 | 0.130 |
Why?
| Diet | 2 | 2020 | 1155 | 0.130 |
Why?
| Adaptation, Psychological | 1 | 2000 | 557 | 0.130 |
Why?
| Neutrophils | 1 | 2021 | 1233 | 0.130 |
Why?
| Mitochondria | 1 | 2021 | 786 | 0.130 |
Why?
| Cardiovascular Diseases | 3 | 2017 | 1802 | 0.130 |
Why?
| Tertiary Prevention | 1 | 2014 | 3 | 0.130 |
Why?
| Alcohol Drinking | 1 | 2020 | 652 | 0.130 |
Why?
| Vasodilation | 3 | 2013 | 457 | 0.130 |
Why?
| Neoplasms | 2 | 2017 | 2179 | 0.120 |
Why?
| Focus Groups | 1 | 2016 | 387 | 0.120 |
Why?
| C-Reactive Protein | 5 | 2018 | 364 | 0.120 |
Why?
| Drug Therapy, Combination | 2 | 2021 | 965 | 0.120 |
Why?
| Respiratory Mucosa | 1 | 2016 | 254 | 0.120 |
Why?
| Blood Pressure | 2 | 2017 | 1664 | 0.110 |
Why?
| Bacteroidaceae Infections | 1 | 2012 | 4 | 0.110 |
Why?
| Secondary Prevention | 1 | 2014 | 227 | 0.110 |
Why?
| Porphyromonas gingivalis | 1 | 2012 | 15 | 0.110 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 147 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2020 | 869 | 0.110 |
Why?
| Family Health | 2 | 2013 | 201 | 0.110 |
Why?
| Immune Tolerance | 1 | 2014 | 334 | 0.110 |
Why?
| Primary Prevention | 1 | 2014 | 185 | 0.110 |
Why?
| Vitamin D | 2 | 2022 | 354 | 0.110 |
Why?
| Stress, Psychological | 1 | 2020 | 976 | 0.110 |
Why?
| Periodontitis | 1 | 2012 | 42 | 0.110 |
Why?
| Population Surveillance | 1 | 2015 | 413 | 0.110 |
Why?
| Health | 1 | 2012 | 81 | 0.110 |
Why?
| Arthrography | 1 | 2011 | 22 | 0.100 |
Why?
| Telomere Shortening | 2 | 2024 | 18 | 0.100 |
Why?
| Delayed Diagnosis | 1 | 2012 | 79 | 0.100 |
Why?
| Predictive Value of Tests | 3 | 2013 | 1868 | 0.100 |
Why?
| Pneumonia, Bacterial | 1 | 2013 | 110 | 0.100 |
Why?
| Breast Neoplasms | 1 | 2023 | 1965 | 0.100 |
Why?
| Proportional Hazards Models | 3 | 2021 | 1125 | 0.100 |
Why?
| Disease Susceptibility | 3 | 2021 | 331 | 0.100 |
Why?
| Time-to-Treatment | 1 | 2012 | 149 | 0.100 |
Why?
| Follow-Up Studies | 4 | 2019 | 4596 | 0.100 |
Why?
| Labor, Induced | 1 | 2011 | 30 | 0.100 |
Why?
| Logistic Models | 5 | 2020 | 1901 | 0.100 |
Why?
| Reproducibility of Results | 3 | 2020 | 2874 | 0.100 |
Why?
| Phenotype | 4 | 2023 | 3004 | 0.100 |
Why?
| Longitudinal Studies | 4 | 2020 | 2513 | 0.100 |
Why?
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.100 |
Why?
| Cyclophosphamide | 1 | 2011 | 222 | 0.090 |
Why?
| Air Pollution | 1 | 2013 | 209 | 0.090 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1185 | 0.090 |
Why?
| Rituximab | 1 | 2011 | 155 | 0.090 |
Why?
| Immunoglobulins, Intravenous | 1 | 2011 | 128 | 0.090 |
Why?
| Statistics, Nonparametric | 1 | 2010 | 403 | 0.090 |
Why?
| Vasodilator Agents | 1 | 2012 | 328 | 0.090 |
Why?
| Colorado | 3 | 2020 | 4196 | 0.090 |
Why?
| Menopause | 1 | 2012 | 266 | 0.090 |
Why?
| Treatment Outcome | 3 | 2021 | 9346 | 0.090 |
Why?
| Community-Institutional Relations | 1 | 2009 | 91 | 0.090 |
Why?
| Respiratory Insufficiency | 1 | 2013 | 290 | 0.090 |
Why?
| Aging | 1 | 2019 | 1677 | 0.090 |
Why?
| Interleukin-6 | 3 | 2021 | 692 | 0.080 |
Why?
| Aspirin | 1 | 2011 | 334 | 0.080 |
Why?
| Odds Ratio | 3 | 2018 | 996 | 0.080 |
Why?
| Alleles | 3 | 2019 | 832 | 0.080 |
Why?
| Disease Outbreaks | 1 | 2010 | 322 | 0.080 |
Why?
| Obesity | 1 | 2020 | 2751 | 0.080 |
Why?
| Societies, Medical | 2 | 2021 | 703 | 0.080 |
Why?
| Adrenal Cortex Hormones | 1 | 2011 | 521 | 0.070 |
Why?
| Brachial Artery | 3 | 2013 | 181 | 0.070 |
Why?
| Stroke | 1 | 2015 | 1046 | 0.070 |
Why?
| Contraceptives, Oral, Hormonal | 1 | 2006 | 23 | 0.070 |
Why?
| Capillaries | 1 | 2005 | 103 | 0.070 |
Why?
| Environment | 2 | 2019 | 346 | 0.060 |
Why?
| Premenopause | 2 | 2017 | 108 | 0.060 |
Why?
| Radiography, Thoracic | 1 | 2005 | 164 | 0.060 |
Why?
| Arthritis, Juvenile | 1 | 2005 | 42 | 0.060 |
Why?
| Healthy Volunteers | 2 | 2017 | 201 | 0.060 |
Why?
| Bronchoscopy | 1 | 2005 | 247 | 0.060 |
Why?
| Immunity, Mucosal | 2 | 2014 | 86 | 0.060 |
Why?
| Interleukin-2 | 2 | 2016 | 417 | 0.060 |
Why?
| Phosphopyruvate Hydratase | 1 | 2023 | 34 | 0.060 |
Why?
| Pulmonary Alveoli | 1 | 2005 | 384 | 0.060 |
Why?
| Vimentin | 1 | 2023 | 62 | 0.060 |
Why?
| Antibodies | 1 | 2005 | 392 | 0.050 |
Why?
| Surveys and Questionnaires | 2 | 2014 | 4709 | 0.050 |
Why?
| Body Mass Index | 2 | 2020 | 2092 | 0.050 |
Why?
| Biopsy | 1 | 2005 | 1079 | 0.050 |
Why?
| Immunoglobulins | 2 | 2015 | 154 | 0.050 |
Why?
| Telomere | 1 | 2024 | 204 | 0.050 |
Why?
| Multivariate Analysis | 2 | 2021 | 1474 | 0.050 |
Why?
| Janus Kinase Inhibitors | 1 | 2021 | 10 | 0.050 |
Why?
| Immunosuppressive Agents | 1 | 2005 | 683 | 0.050 |
Why?
| Tissue Distribution | 1 | 2022 | 334 | 0.050 |
Why?
| Herpesvirus 4, Human | 1 | 2022 | 126 | 0.050 |
Why?
| Hydroxyeicosatetraenoic Acids | 1 | 2021 | 41 | 0.050 |
Why?
| Carotid Arteries | 2 | 2013 | 184 | 0.050 |
Why?
| Xenobiotics | 1 | 2021 | 25 | 0.050 |
Why?
| Putrescine | 1 | 2020 | 4 | 0.050 |
Why?
| Butyric Acid | 1 | 2020 | 5 | 0.050 |
Why?
| Vitamins | 1 | 2022 | 159 | 0.050 |
Why?
| Mice | 3 | 2022 | 15528 | 0.050 |
Why?
| Docosahexaenoic Acids | 1 | 2021 | 70 | 0.050 |
Why?
| Genetic Markers | 1 | 2022 | 348 | 0.050 |
Why?
| Microbiota | 2 | 2021 | 656 | 0.050 |
Why?
| Spermidine | 1 | 2020 | 18 | 0.050 |
Why?
| Tomography, X-Ray Computed | 2 | 2012 | 2436 | 0.050 |
Why?
| Caprylates | 1 | 2020 | 26 | 0.050 |
Why?
| Europe | 1 | 2021 | 356 | 0.050 |
Why?
| Phosphatidylethanolamines | 1 | 2020 | 66 | 0.050 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2020 | 3 | 0.050 |
Why?
| Carnitine | 1 | 2020 | 65 | 0.050 |
Why?
| Chemokine CXCL13 | 1 | 2020 | 7 | 0.050 |
Why?
| B-Cell Activating Factor | 1 | 2020 | 18 | 0.050 |
Why?
| Disease Models, Animal | 1 | 2010 | 3730 | 0.050 |
Why?
| Synovial Fluid | 1 | 2020 | 56 | 0.050 |
Why?
| Chemokine CXCL9 | 1 | 2020 | 22 | 0.050 |
Why?
| Acute-Phase Proteins | 1 | 2020 | 67 | 0.050 |
Why?
| Interleukin-8 | 1 | 2021 | 249 | 0.050 |
Why?
| Survival Analysis | 2 | 2017 | 1267 | 0.050 |
Why?
| Methionine | 1 | 2020 | 145 | 0.050 |
Why?
| Chemokine CXCL10 | 1 | 2020 | 40 | 0.050 |
Why?
| Immunophenotyping | 1 | 2020 | 278 | 0.050 |
Why?
| Interleukin-1alpha | 1 | 2020 | 56 | 0.040 |
Why?
| Fluorescent Antibody Technique | 1 | 2020 | 410 | 0.040 |
Why?
| Antibody Specificity | 1 | 2020 | 184 | 0.040 |
Why?
| Ontario | 1 | 2000 | 109 | 0.040 |
Why?
| Interinstitutional Relations | 1 | 2000 | 55 | 0.040 |
Why?
| Tryptophan | 1 | 2020 | 139 | 0.040 |
Why?
| Baltimore | 1 | 2019 | 42 | 0.040 |
Why?
| International Cooperation | 1 | 2020 | 177 | 0.040 |
Why?
| Interferons | 1 | 2020 | 151 | 0.040 |
Why?
| Prognosis | 2 | 2021 | 3443 | 0.040 |
Why?
| Endotoxins | 1 | 2020 | 234 | 0.040 |
Why?
| Pregnancy | 1 | 2011 | 5694 | 0.040 |
Why?
| Consensus | 1 | 2021 | 534 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2023 | 634 | 0.040 |
Why?
| Interleukin-1beta | 1 | 2021 | 379 | 0.040 |
Why?
| Clinical Decision-Making | 1 | 2021 | 277 | 0.040 |
Why?
| Epitopes, B-Lymphocyte | 1 | 2018 | 15 | 0.040 |
Why?
| Dysbiosis | 1 | 2020 | 147 | 0.040 |
Why?
| B-Lymphocytes | 1 | 2023 | 770 | 0.040 |
Why?
| Nurses | 1 | 2020 | 142 | 0.040 |
Why?
| Genotype | 2 | 2018 | 1882 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2022 | 542 | 0.040 |
Why?
| Reactive Oxygen Species | 1 | 2021 | 576 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2020 | 239 | 0.040 |
Why?
| Interleukins | 1 | 2020 | 242 | 0.040 |
Why?
| Forecasting | 1 | 2020 | 354 | 0.040 |
Why?
| Genetic Testing | 1 | 2020 | 389 | 0.040 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2023 | 702 | 0.040 |
Why?
| Membrane Glycoproteins | 1 | 2020 | 446 | 0.040 |
Why?
| Gene Frequency | 1 | 2019 | 513 | 0.040 |
Why?
| Decision Support Techniques | 1 | 2021 | 364 | 0.040 |
Why?
| Goserelin | 1 | 2017 | 8 | 0.040 |
Why?
| Raloxifene Hydrochloride | 1 | 2017 | 13 | 0.040 |
Why?
| Phylogeny | 1 | 2021 | 817 | 0.040 |
Why?
| Amino Acids | 1 | 2021 | 465 | 0.040 |
Why?
| Fertility Agents, Female | 1 | 2017 | 19 | 0.040 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2019 | 2062 | 0.040 |
Why?
| Selective Estrogen Receptor Modulators | 1 | 2017 | 26 | 0.040 |
Why?
| Leuprolide | 1 | 2017 | 20 | 0.040 |
Why?
| Estrogens, Conjugated (USP) | 1 | 2017 | 34 | 0.040 |
Why?
| Genes, Immunoglobulin Light Chain | 1 | 2016 | 5 | 0.040 |
Why?
| Genes, Immunoglobulin Heavy Chain | 1 | 2016 | 9 | 0.040 |
Why?
| Phosphofructokinase-2 | 1 | 2016 | 14 | 0.040 |
Why?
| Aromatase Inhibitors | 1 | 2017 | 52 | 0.040 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.040 |
Why?
| Th17 Cells | 1 | 2016 | 57 | 0.040 |
Why?
| Bacteria | 1 | 2023 | 757 | 0.040 |
Why?
| Complement Activation | 1 | 2019 | 350 | 0.040 |
Why?
| Adolescent | 4 | 2021 | 18483 | 0.030 |
Why?
| Protective Factors | 1 | 2016 | 92 | 0.030 |
Why?
| Antibodies, Monoclonal | 1 | 2022 | 1285 | 0.030 |
Why?
| Models, Statistical | 1 | 2020 | 636 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2023 | 1774 | 0.030 |
Why?
| Health Education | 1 | 2018 | 318 | 0.030 |
Why?
| Carrier Proteins | 1 | 2020 | 726 | 0.030 |
Why?
| Patient Satisfaction | 1 | 2000 | 610 | 0.030 |
Why?
| Androgens | 1 | 2017 | 168 | 0.030 |
Why?
| Gonadotropin-Releasing Hormone | 1 | 2017 | 193 | 0.030 |
Why?
| Transcriptome | 1 | 2021 | 756 | 0.030 |
Why?
| Symptom Assessment | 1 | 2016 | 123 | 0.030 |
Why?
| Leukocyte Count | 1 | 2015 | 305 | 0.030 |
Why?
| Hypercholesterolemia | 1 | 2015 | 93 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2019 | 6562 | 0.030 |
Why?
| RNA, Messenger | 1 | 2022 | 2661 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2018 | 1158 | 0.030 |
Why?
| Motivation | 1 | 2018 | 506 | 0.030 |
Why?
| HLA-DRB1 Chains | 1 | 2014 | 97 | 0.030 |
Why?
| Etanercept | 1 | 2013 | 51 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2016 | 755 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 452 | 0.030 |
Why?
| Testosterone | 1 | 2017 | 351 | 0.030 |
Why?
| Pneumocystis carinii | 1 | 2013 | 7 | 0.030 |
Why?
| Geographic Information Systems | 1 | 2013 | 40 | 0.030 |
Why?
| Communication | 1 | 2018 | 761 | 0.030 |
Why?
| Interleukin-9 | 1 | 2012 | 11 | 0.030 |
Why?
| Oral Health | 1 | 2014 | 148 | 0.030 |
Why?
| Comorbidity | 1 | 2017 | 1527 | 0.030 |
Why?
| Dietary Supplements | 1 | 2016 | 467 | 0.030 |
Why?
| Cell Membrane | 1 | 2016 | 710 | 0.030 |
Why?
| Fatal Outcome | 1 | 2013 | 287 | 0.030 |
Why?
| Life Style | 1 | 2014 | 431 | 0.030 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 143 | 0.030 |
Why?
| Immunologic Factors | 1 | 2014 | 225 | 0.030 |
Why?
| Connective Tissue Diseases | 1 | 2012 | 57 | 0.030 |
Why?
| Mutation | 1 | 2022 | 3457 | 0.020 |
Why?
| Particulate Matter | 1 | 2013 | 244 | 0.020 |
Why?
| Exercise | 1 | 2021 | 1657 | 0.020 |
Why?
| Polymerase Chain Reaction | 1 | 2014 | 1012 | 0.020 |
Why?
| Environmental Monitoring | 1 | 2013 | 296 | 0.020 |
Why?
| Erythrocytes | 1 | 2016 | 641 | 0.020 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 304 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2012 | 526 | 0.020 |
Why?
| Overweight | 1 | 2014 | 502 | 0.020 |
Why?
| Socioeconomic Factors | 1 | 2014 | 1129 | 0.020 |
Why?
| Internet | 1 | 2014 | 633 | 0.020 |
Why?
| Body Composition | 1 | 2013 | 653 | 0.020 |
Why?
| Self Report | 1 | 2013 | 699 | 0.020 |
Why?
| Interferon-gamma | 1 | 2012 | 737 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 716 | 0.020 |
Why?
| Veterans | 1 | 2018 | 1213 | 0.020 |
Why?
| Bottle Feeding | 1 | 2007 | 22 | 0.020 |
Why?
| Diabetes Mellitus | 1 | 2015 | 945 | 0.020 |
Why?
| Algorithms | 1 | 2014 | 1543 | 0.020 |
Why?
| Gene Expression Regulation | 1 | 2016 | 2446 | 0.020 |
Why?
| Histocompatibility Testing | 1 | 2007 | 123 | 0.020 |
Why?
| Hypertension | 1 | 2015 | 1203 | 0.020 |
Why?
| Tobacco Smoke Pollution | 1 | 2007 | 233 | 0.010 |
Why?
| Siblings | 1 | 2005 | 235 | 0.010 |
Why?
| Child | 2 | 2007 | 19137 | 0.010 |
Why?
| Child, Preschool | 1 | 2007 | 9493 | 0.010 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2006 | 3361 | 0.010 |
Why?
|
|
Deane's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|